Humanin: The Neuroprotective Mitochondrial Peptide
Last updated: November 2026
Humanin is the first discovered mitochondrial-derived peptide: a 24-amino acid sequence encoded within the mitochondrial genome. Identified in 2001 as a neuroprotective factor, it blocks apoptosis and reduces oxidative stress in cell studies, improves insulin sensitivity in rodents, and its circulating levels decline with age.
in Sequence
Discovered
Track your vials and inventory on paper
Printable vial and inventory sheets for your own research records. Every value is entered by you. Free to build and preview; $5/month to unlock printing.
The 2001 Discovery Story
Found in a functional screen for factors that rescue neurons from Alzheimer's-linked cell death, Humanin changed how we think about mitochondria.
In 2001, Hashimoto and colleagues at Keio University School of Medicine in Tokyo were screening a cDNA library from the occipital lobe of an Alzheimer's patient. A short, previously unknown sequence (later traced to an open reading frame in the mitochondrial 16S rRNA region) completely protected neurons from amyloid-beta-induced cell death. They named it Humanin.
Humanin is encoded within the 16S rRNA gene of the mitochondrial genome, the same genome that manages cellular energy production. It is the first known peptide derived from mitochondrial DNA. An identical open reading frame also exists in the nuclear genome; Guo et al. (2003) speculated that Humanin arose in mitochondria and moved to the nucleus.
The Hashimoto lab found that synthetic Humanin at micromolar concentrations, and its S14G analog at nanomolar concentrations, prevented neuron death triggered by familial Alzheimer's disease genes (APP, PSEN1, PSEN2) and amyloid-beta in cell cultures.
Humanin is not just intracellular. In the original study it was secreted into the culture medium (Hashimoto et al., 2001), and it circulates in blood. Mitochondrial-derived peptides like it are described as mitochondrial hormones (Lee et al., 2016).
Humanin is detectable in human circulation, and circulating levels are lower in older adults (Muzumdar et al., 2009). This opened the door to studying it as both a biomarker and a potential therapeutic target.
How Humanin Works
Humanin operates through multiple pathways: blocking cell death, reducing oxidative stress, and modulating growth factor signaling.
Humanin binds the pro-apoptotic protein BAX and prevents it from moving from the cytosol to mitochondria, and in vitro it suppressed cytochrome c release from isolated mitochondria (Guo et al., 2003).
Humanin's protection against Alzheimer's-related neurotoxicity runs in large part through activation of the JAK2/STAT3 signaling axis, which a 2009 review calls a major transducer of its neuroprotective activity (Chiba et al., 2009).
Humanin binds IGFBP-3, a protein that regulates IGF activity, without blocking IGF-1 from binding IGFBP-3; the interaction can either add to or oppose IGFBP-3's effects on cell survival depending on cell type (Ikonen et al., 2003).
In cell studies, Humanin reduced reactive oxygen species (ROS) and cell death under oxidative stress; in human aortic endothelial cells, pretreatment cut oxidized-LDL–induced ROS and apoptosis (Bachar et al., 2010).
In rodent studies, Humanin improved insulin sensitivity through hypothalamic STAT-3 signaling; its effect on liver insulin action was centrally mediated rather than direct (Muzumdar et al., 2009).
Humanin is expressed in the endothelial lining of human blood vessels, and in cultured endothelial cells it reduced oxidized-LDL–induced apoptosis (Bachar et al., 2010).
Age-Related Decline
Humanin levels drop with age.
Circulating Humanin was decreased with age in both humans and mice (Muzumdar et al., 2009). In that study's human data, plasma Humanin was about 40% lower at ages 81–110 than at ages 45–65 (roughly 800 vs 1,400 pg/mL, Figure 8B). People under 45 were not sampled, so the size of any decline from young adulthood is unknown.
The authors of the 2009 study proposed that the age-related decline in Humanin could play a role in age-related diseases, including type 2 diabetes and Alzheimer's disease (Muzumdar et al., 2009). That is a hypothesis, not a tested result.
What the Research Shows
Preclinical evidence comes from cell and animal models of Alzheimer's disease and metabolic disease. Human data is limited to observational measurements: circulating levels and staining of blood-vessel tissue.
Alzheimer's Disease Research
Metabolic Syndrome Research
Additional Protective Effects
The Mitochondrial Peptide Family
Humanin belongs to a growing family of mitochondrial-derived peptides that includes MOTS-c (Lee et al., 2016). SS-31 and Epithalon, shown alongside, are synthetic peptides rather than mitochondria-derived ones.
24-AA. First MDP discovered. Anti-apoptotic, neuroprotective. Declines with age. JAK2/STAT3 and BAX inhibition.
16-AA mitochondrial-derived peptide. Targets skeletal muscle and enhances glucose metabolism (Lee et al., 2016).
Targets cardiolipin in inner mitochondrial membrane. FDA-approved in 2025 as Forzinity for Barth syndrome. Restores cristae structure.
SS-31 approval status: Forzinity (elamipretide) prescribing information, DailyMed (NDA 215244).
4-AA tetrapeptide bioregulator, studied for telomerase activation and for circadian and antioxidant effects.
Browse all researched peptides, mechanisms, and clinical data in our interactive compound database.
Full library of HighPeptides research infographics — longevity, healing, cognitive, metabolic, and more.
Safety Considerations
Human safety data is sparse, and the animal studies cited here were not designed as toxicology studies. Risk assessment is extrapolated from animal and cell models.
Ideal Candidate Profile
Humanin research is most relevant for specific clinical contexts. Age-related neurodegeneration and metabolic dysfunction are the primary areas of interest.
- Adults interested in longevity and mitochondrial health research
- Research interest in Alzheimer's disease biomarker tracking
- Metabolic syndrome with concurrent interest in mitochondrial function
- Those following mitochondrial peptide research (MOTS-c, SS-31)
- Anyone with active or history of hormone-sensitive cancers
- Currently pregnant or breastfeeding
- Individuals on IGF-1 or insulin therapy
- Anyone expecting clinical benefits (no human efficacy trials completed)
- Those seeking a standalone Alzheimer's treatment
Important framing: Humanin is currently a research tool, not a therapeutic. The appropriate use is in clinical research contexts with proper oversight. Consumer use is premature given the current evidence base.
Key Study Citations
Key Takeaways
- First mitochondrial-derived peptide, discovered 2001
- 24-amino acid sequence encoded in mtDNA (16S rRNA region)
- Anti-apoptotic in cell studies: blocks BAX activation (Guo et al., 2003) and signals through JAK2/STAT3 (Chiba et al., 2009)
- Reduces amyloid-beta toxicity in cell models; the synthetic analog S14G-humanin reduced amyloid pathology in mice
- Circulating levels are lower in older humans and mice
- Improved insulin sensitivity and lowered blood glucose in rodent studies
- Circulates in blood; mitochondrial-derived peptides act as mitochondrial hormone-like signals (Lee et al., 2016)
- No completed human Phase 2/3 clinical trials
- Optimal dose, route, and frequency in humans not established
- Long-term safety profile in humans unknown
- Net effect of the Humanin–IGFBP-3 interaction on growth factor signaling
- Whether supplemental Humanin actually reduces Alzheimer's risk in humans
- Bioavailability and half-life in human circulation
- Cancer risk implications of chronic IGF-1 axis modulation
Verified Research Source
Research compounds from Swiss Chems.
Affiliate links support HighPeptides at no extra cost. Swiss Chems publishes third-party HPLC COAs for selected products (vendor-published, a claim to verify).
Recommended Products
Supplements related to mitochondrial research.
Affiliate links support HighPeptides at no extra cost.
Related Resources
Want the Complete Protocol Guide?
A broad reference to 20+ research compounds, all in one place.
Get the Guide: $19 (normally $29) →
The Peptide Buyer’s Playbook ($19)
This page is for educational and informational purposes only. Humanin is a research peptide not approved by the FDA or any regulatory body. All data cited comes from preclinical studies (cell culture and animal models) and human observational data (circulating levels and blood-vessel tissue staining). No large human clinical trials have been completed. The safety and efficacy of Humanin in humans has not been established. Always consult a qualified, licensed healthcare provider before starting any new compound. Nothing on this page constitutes medical advice.
Get the Free 2026 Peptide Protocol Stack
Twelve compounds across four pillars: metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.